Cocrystal Pharma, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, reporting financial results for both the three and nine months ended on that date.
Key Highlights
- Net loss of $8.907 million for the nine months ended September 30, 2026, compared to a net loss of $6.405 million for the same period in 2025, according to the filing.
- Q3 2026 net loss of $3.444 million ($0.20 per share, basic and diluted), versus a net loss of $2.049 million ($0.19 per share) in Q3 2025.
- Government contract revenue of $435 thousand was recorded for the nine months ended September 30, 2026, with no comparable revenue in the prior-year period.
- Private placement raised $5.001 million through a related-party sale of 5,474 thousand shares of common stock during Q3 2026.
- Cash and restricted cash ended at $4.948 million as of September 30, 2026, down from $7.100 million at the start of the period.
- Shares outstanding increased to 19,265 thousand as of September 30, 2026, from 13,784 thousand as of December 31, 2025.
- Accumulated deficit reached $351.156 million as of September 30, 2026, up from $342.249 million at December 31, 2025.
Cocrystal Pharma's Q3 2026 Operating Results and Capital Activity
Cocrystal Pharma, Inc. (NASDAQ:COCP), a clinical-stage biopharmaceutical company based in Bothell, WA, reported a net loss of $3.444 million for the three months ended September 30, 2026, according to the filing. Total operating expenses for the quarter were $3.594 million, composed of $1.978 million in research and development costs and $1.616 million in general and administrative expenses. The company recorded $105 thousand in government contract revenue during the quarter, with no such revenue in the comparable prior-year period.
For the nine months ended September 30, 2026, the company disclosed total operating expenses of $9.464 million, compared to $6.538 million for the same period in 2025. Research and development spending rose to $5.491 million from $3.436 million year-over-year, while general and administrative expenses increased to $3.973 million from $3.102 million. The net loss per common share on a basic and diluted basis was $0.59 for the nine-month period, versus $0.61 in the prior-year period, with weighted average shares outstanding of 15,011 thousand and 10,449 thousand, respectively.
The company's balance sheet as of September 30, 2026, showed total assets of $6.773 million and total liabilities of $4.098 million, leaving total stockholders' equity of $2.675 million, down from $6.331 million at December 31, 2025. Net cash used in operating activities was $7.152 million for the nine months ended September 30, 2026. The company raised $5.000 million in proceeds from a private placement to a related party during the period, partially offsetting the cash outflow. As of November 16, 2026, the filing stated that approximately 19,264,893 shares of common stock were outstanding.
What Was Disclosed
Cocrystal Pharma filed its quarterly report covering the period ended September 30, 2026, disclosing a nine-month net loss of $8.907 million, a related-party private placement of $5.001 million, the initiation of government contract revenue, and a reduction in cash and restricted cash to $4.948 million.





Please wait processing your request...